Clinical Trials
10 trialsNCT05503550 2025-12-16
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
No longer available
NCT05757973 2025-12-09
Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Approved for marketing
NCT05164250 2025-11-10
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron Pharmaceuticals
Approved for marketing
NCT05463939 2025-06-15
Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
Janssen Research & Development, LLC
Approved for marketing
NCT05238311 2025-02-04
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
Pfizer
No longer available
NCT05462639 2024-08-09
MAGNETISMM17
Pfizer
No longer available
NCT02568943 2020-04-08
An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
Novartis
No longer available
NCT01632826 2019-11-12
PEXIUS
Celgene
Approved for marketing
NCT00423826 2016-02-29
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Barbara Ann Karmanos Cancer Institute
No longer available
NCT00063791 2007-02-14
A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE
Millennium Pharmaceuticals, Inc.
No longer available